Li Auto Inc vs ResMed Inc. — how do they compare? Li Auto Inc trades at $12.57 (market cap $12.28B), while ResMed Inc. trades at $222.47 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 2.7× Li Auto Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| LI | RMD | |
|---|---|---|
Market Cap | $12.28B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.69 | $293.73 |
52-Week Low | $11.74 | $182.82 |
Enterprise Value | $1.11B | $31.97B |
Dividend Yield | — | 1.17% |
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.84, down 0.85% on the day, with bearish technical signals and mixed earnings performance. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle launches including the Li L6 and L8 aim to boost deliveries amid intense Chinese EV competition.
While analyst consensus suggests moderate upside to $14.80 price target, significant risks include declining profitability, negative cash flow trends, and competitive pressures in China's EV market. The stock faces headwinds from execution challenges and macroeconomic uncertainties affecting the auto sector.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Trailing returns across standard periods
Latest headlines on both assets
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →